Raimundas Voishka, country manager Lithuania and Belarus at Pfizer, highlights the increasing openness of the Baltic region towards innovation and stresses the commitment of Pfizer to bringing innovative as well as added-value medicines to the region.
You have more than 20 years of experience in the Lithuanian pharmaceutical industry. What would you highlight as the most significant change on the Lithuanian pharmaceutical market over the last recent years?
"Pfizer significantly invests in clinical research in Lithuania but also in the Baltic region; being positioned as one of the strongest players in this front."
